Skip to content

Decoding and Characteristic Analysis of Immunity at Different Stages in Patients Undergoing Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation

Decoding and Characteristic Analysis of Immunity at Different Stages in Patients Undergoing Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500098916
Enrollment
Unknown
Registered
2025-03-14
Start date
2025-04-01
Completion date
Unknown
Last updated
2025-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hematologic malignancies

Interventions

Haplo-HSCT group:None

Sponsors

The Second Affiliated Hospital of Army Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Eligibility criteria: 1 Patients who were first diagnosed with acute leukemia in our center, including acute myeloid leukemia and acute lymphoblastic leukemia, had indications for transplantation, were eligible for physical examination, and planned to undergo haploidentical hematopoietic stem cell transplantation after induction chemotherapy, regardless of sex, aged 18-50 years old; 2KPS score >60 points, predicted survival time >6 months; 3 without serious damage of vital organs: 1) creatinine =2g/dl; 3) cardiac ejection index >55%; 4) heme >9g/dL, bilirubin < 2.0mg/dl; 4 no contraindication of hematopoietic stem cell transplantation; 5 Voluntarily participated in this study and signed the informed consent.

Exclusion criteria

Exclusion criteria: Exclusion criteria: 1 Active bleeding due to medication or low platelet count; 2 Pregnant or breastfeeding women; 3 Patients with other malignant tumors that require treatment; 4 Patients with clinical symptoms of cerebral dysfunction or severe psychiatric disorders that prevent understanding or compliance with the study protocol; 5 Patients with a history of severe acute allergic reactions; 6 Uncontrolled active infections; 7 Uncontrolled severe diabetes, autoimmune diseases, severe hypertension, and other serious illnesses; 8 Insufficient residual bone marrow blood/peripheral blood samples from the subject's routine bone marrow aspiration, less than 2ml; 9 Patients deemed unsuitable for clinical trials by the researchers for other reasons.

Design outcomes

Primary

MeasureTime frame
1-year Overall Survival;

Secondary

MeasureTime frame
100-day incidence rate of aGVHD;1-year incidence rate of cGVHD;

Countries

China

Contacts

Public ContactXi Zhang

The Second Affiliated Hospital of Army Medical University

zhangxxi@sina.com+86 138 0831 0064

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026